Endo International plc (NASDAQ:ENDP) [Trend Analysis] plunged reacts as active mover, shares a decrease -1.47% to traded at $15.41 and the percentage gap between open changing to regular change was 0.00%. Endo International plc (ENDP) declared that one of its operating companies, Par Pharmaceutical, has begun shipping ezetimibe 10 mg tablets, the generic version of Merck’s ZETIA. Par Pharmaceutical is the marketer and distributor of the product in the U.S., and is entitled to Hatch-Waxman generic marketing exclusivity based on the first-to-file ANDA status of its licensing partners, Glenmark Pharmaceuticals, USA, with whom Par will share profits.
ZETIA is indicated for use along with a healthy diet to reduce elevated LDL cholesterol in patients with hyperlipidemia.According to IMS Health data, U.S. sales of ZETIA are approximately $2.614 billion for the 12 months ended September 30, 2016. The firm’s current ratio calculated as 0.80 for the most recent quarter. The firm past twelve months price to sales ratio was 0.89 and price to cash ratio remained 6.12. As far as the returns are concern, the return on equity was recorded as -2.10% and return on investment was 0.90% while its return on asset stayed at -0.70%. The firm has total debt to equity ratio measured as 1.37.
Osisko Gold Royalties Ltd. (NYSE:OR) reported appointment of Mr. Jacques Perron to its Board of Directors. Sean Roosen, Chair of the Board of Directors and Chief Executive Officer noted: “We are very pleased to have a mine operator with Mr. Perron’s experience and leadership abilities join our Board. Jacques’ mining skill set will well complement the industry experience of our current Board members.”
He is a member of the Board of Directors of Centerra Gold since October 2016, and is also a director of the Canadian Mineral Education Foundation since 2007. Mr. Perron holds a Bachelor of Science degree in Mining Engineering from l’École Polytechnique de Montréal and has membership in Professional Engineers of Ontario and l’Ordre des Ingénieurs du Québec.